ArticleLipids2011
Oral docosapentaenoic acid (22:5n-3) is differentially incorporated into phospholipid pools and differentially metabolized to eicosapentaenoic acid in tissues from young rats.
Article in Lipids, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 38 citations in OpenAlex.
- A short-term n-3 DPA supplementation study in humans.European journal of nutrition · 2013Trial
- Supplementation with plant-derived oils rich in omega-3 polyunsaturated fatty acids for lamb production.Veterinary and animal science · 2018Review
- MAG-DPA curbs inflammatory biomarkers and pharmacological reactivity in cytokine-triggered hyperresponsive airway models.Pharmacology research & perspectives · 2016Article
- Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA.Frontiers in aging neuroscience · 2015Review
- Effect of stearidonic acid-enriched soybean oil on fatty acid profile and metabolic parameters in lean and obese Zucker rats.Lipids in health and disease · 2013Article
- Review
- Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer.Prostate cancer · 2013Article
- The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A meta-analysis.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study assessed the effect of oral supplementation with docosapentaenoic acid (DPA, 22:5n-3) on the levels of serum and tissue lipid classes and their fatty acid compositions including individual phospholipid types in rat liver, heart, and kidney. Sprague-Dawley rats received daily oral gavage over 10 days as corn oil without (controls) or with purified DPA in free fatty acid form (21.2 mg/day). The DPA group exhibited significantly lower serum lipid concentrations. The concentrations in μmol/100 g serum or μmol/g tissue of DPA in the total lipid (TL) were higher by 2.3-, 2.4-, 10.9-, and 5.1-fold in the DPA group of serum, liver, heart, and kidney, respectively, with the phospholipids (PL) being the major DPA reservoir (45.2-52.1% of the DPA in the TL). No significant differences in DHA (22:6n-3) amounts in TL appeared. The highest relative mol% values as DPA were in heart tissue (means of 11.1% in PL and 16.2% in phosphatidylinositol) and lowest in kidney. The EPA (20:5n-3) concentrations were markedly higher in the DPA group and most pronounced in the kidney (5.1 times higher in the TL as compared to controls) relative to liver and heart yielding an estimated apparent % conversion of DPA to EPA of 67% and EPA:DPA ratios reaching 5.74 in kidney phosphatidylethanolamine. The serum lipid-lowering potential of dietary DPA and its impact in the kidney with the derived EPA warrants investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.